EOLS Evolus, Inc.
8-K Current Report
Filed: March 3, 2026
Health Care
Pharmaceutical PreparationsEvolus, Inc. (EOLS) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 2.02: Results of Operations and Financial Condition
AI Filing Analysis8-K
Item 1.01 · Entry into a Material Definitive Agreement
- • New $30M senior secured revolving credit facility with Eclipse Business Capital, maturing March 3, 2029
- • Interest rate: SOFR (2.0% floor) + 4.25% margin, with potential downward adjustments based on coverage ratio and availability
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings results released March 3, 2026 — full figures in Exhibit 99.1
- • EOLS is a medical aesthetics company (neuromodulator Jeuveau); results reflect competitive botulinum toxin market dynamics
Other Evolus, Inc. 8-K Filings
Get deeper insights on Evolus, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.